CKD-512

CKD-512 is an orally bioavailable small molecule antagonist of the Adenosine A2a receptor (A2aR), developed by Chong Kun Dang Pharmaceutical. In the tumor microenvironment (TME), high levels of extracellular adenosine bind to A2a receptors on immune cells, such as T cells and natural killer (NK) cells, triggering an immunosuppressive signal that hinders the body's anti-tumor response. By selectively blocking the A2a receptor, CKD-512 aims to reverse this adenosine-mediated immunosuppression and restore immune effector function. It is currently being investigated in Phase Ia/Ib clinical trials as a monotherapy and in combination with the PD-1 inhibitor pembrolizumab for the treatment of patients with advanced or metastatic solid tumors who have failed standard available therapies.